Dr. Cameron J. Kemal, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 1,349
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME160877
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morton Plant Hospital Clearwater, FL
- Mease Countryside Hospital Safety Harbor, FL
- Mease Dunedin Hospital Dunedin, FL
- Morton Plant North Bay Hospital New Port Richey, FL
Medical groups
- Baycare Medical Group, Inc. (1,547 clinicians)
- Morton Plant Health Services Inc (87 clinicians)
- Morton Plant Mease Diagnostic Cardiology LLC (28 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,349
- Services billed
- 3,005
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 114 | 67 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 114 | 113 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 61 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 58 | 43 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 31 | 31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | 15 |
| Ultrasound of heart with probe in esophagus, with report | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Clearwater, FL | 211 |
| Rosuvastatin Calcium Other prescribers in Clearwater, FL | 180 |
| Atorvastatin Calcium Other prescribers in Clearwater, FL | 110 |
| Amlodipine Besylate Other prescribers in Clearwater, FL | 72 |
| Xarelto (rivaroxaban) Other prescribers in Clearwater, FL | 71 |
| Jardiance (empagliflozin) Other prescribers in Clearwater, FL | 70 |
| Furosemide Other prescribers in Clearwater, FL | 52 |
| Ezetimibe Other prescribers in Clearwater, FL | 48 |
| Eliquis (apixaban) Other prescribers in Clearwater, FL | 47 |
| Spironolactone Other prescribers in Clearwater, FL | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 91 payments worth $1,734 in total to this clinician.
| Pfizer Inc. | $387 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $327 |
| Novartis Pharmaceuticals Corporation | $312 |
| Scpharmaceuticals Inc. | $159 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $97.98 |
| Novo Nordisk Inc | $89.74 |
| Alnylam Pharmaceuticals Inc. | $86.02 |
| Amgen Inc. | $77.01 |
| Food and Beverage | $1,720 |
|---|---|
| Education | $14.75 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 12, 2025 | Education VYNDAMAX · CARDIOVASCULAR · in-kind | $8.35 |
| Pfizer Inc. Apr 14, 2025 | Education VYNDAMAX · CARDIOVASCULAR · in-kind | $3.20 |
| Pfizer Inc. May 29, 2025 | Education VYNDAMAX · CARDIOVASCULAR · in-kind | $3.20 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.